New York, New York--(Newsfile Corp. - November 10, 2025) - If you suffered a loss on your Baxter International, Inc. (NYSE: BAX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/baxter-international-inc-lawsuit-submission-form?prid=176438&wire=5&utm_campaign=23or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder a ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of federal securities law violations related to the Novum LVP device, which reportedly suffered systemic defects leading to serious patient risks [3][4]. Group 1: Allegations Against Baxter - The complaint alleges that Baxter and its executives made false or misleading statements regarding the Novum LVP, failing to disclose systemic defects that caused malfunctions, including underinfusion and overinfusion, which posed risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures, leading to continued harm to patients [3]. - As a result of these issues, there was a heightened risk that existing Novum LVPs would be taken out of service, and Baxter would halt all new sales of these pumps [3]. Group 2: Impact on Stock and Legal Proceedings - The true extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [4]. - Investors who purchased Baxter securities between February 23, 2022, and July 30, 2025, are encouraged to discuss their legal rights and options, with a deadline of December 15, 2025, to seek the role of lead plaintiff in the class action [1][5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - Investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by December 15, 2025, to represent other class members [4][6]. Group 2: Allegations Against Baxter - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which caused malfunctions that posed serious risks to patients [6]. - Specific issues included underinfusion, overinfusion, and complete non-delivery of fluids, along with inadequate responses to reported malfunctions and injuries [6]. - The lawsuit claims that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, leading to investor damages when the truth was revealed [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [5]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The deadline to move the Court to serve as lead plaintiff is December 15, 2025, with the lead plaintiff acting on behalf of other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field [4] Group 3: Case Allegations - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to serious risks for patients [5] - Specific claims include that Baxter was aware of multiple device malfunctions and that its remedial measures were inadequate, resulting in a heightened risk of product recalls and sales pauses [5] - The lawsuit asserts that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, causing investor damages when the truth was revealed [5]

Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 15, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Baxter - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to malfunctions and posed serious risks to patients [5]. - Specific issues cited include underinfusion, overinfusion, and complete non-delivery of fluids, along with inadequate remedial measures taken by Baxter in response to reported malfunctions and injuries [5]. - The lawsuit claims that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the true details became public [5].

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the United States [5].

Core Viewpoint - The Baxter Foundation is continuing its partnership with Northwestern University's School of Education and Social Policy to enhance STEM education in the Chicagoland area through a significant financial commitment [1] Group 1: Partnership Details - The partnership aims to provide science, technology, engineering, and math (STEM) programs for students and teachers [1] - The initiative is supported by a three-year grant amounting to $2.6 million from the Baxter Foundation [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025, deadline to become a lead plaintiff in a class action lawsuit [2][4]. Group 1: Class Action Details - Investors who bought Baxter common stock during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and interested parties must act by December 15, 2025, to serve as lead plaintiff [4][6]. - The lawsuit alleges that Baxter misled investors regarding the safety and efficacy of the Novum IQ Large Volume Pump, which suffered systemic defects leading to serious risks for patients [6]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [5]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements since 2013 [5]. Group 3: Case Specifics - The lawsuit claims that Baxter was aware of multiple malfunctions and injuries related to the Novum LVP but failed to adequately address these issues, leading to misleading statements about the product's safety and sales prospects [6].

Core Viewpoint - Baxter International, Inc. is facing a federal securities class action lawsuit due to allegations of misleading investors regarding the safety and performance of its Novum LVP device, which has been linked to serious patient risks and malfunctions [3][4]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of investors who acquired Baxter securities between February 23, 2022, and July 30, 2025, alleging that the company failed to disclose critical safety issues with the Novum LVP [3]. - Allegations include systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, which posed risks of serious injury or death to patients [3]. Safety Concerns - Safety issues regarding the Novum LVP emerged on April 7, 2025, following a whistleblower report about inaccurate infusion [4]. - Baxter issued warning letters to customers about underinfusion risks, initially disclosing only one serious injury, but later acknowledging 79 reports of serious injuries and two patient deaths related to the device [4]. Financial Impact - Following the announcement of a voluntary pause in shipments and installations of the Novum LVP on July 31, 2025, Baxter's share price fell by $6.29, approximately 22.4%, from $28.05 to $21.76 [4].

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud related to the company's product malfunctions and inadequate responses to these issues [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 23, 2022, and July 30, 2025 [1]. - The complaint alleges that Baxter's Novum LVP product suffered systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths linked to these defects, yet their remedial measures were deemed inadequate [2]. Group 2: Implications for Baxter - Due to the ongoing issues with the Novum LVP, there is a heightened risk that customers may be instructed to take these devices out of service, potentially halting all new sales [2]. - Baxter's statements regarding the safety, efficacy, and sales prospects of the Novum LVPs have been characterized as materially false and misleading [2]. Group 3: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 4: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4].